Karanes C - Search Results

1

Microsatellite instability is not a defining genetic feature of acute myeloid leukemogenesis in adults: results of a retrospective study of 132 patients and review of the literature.

Rimsza LM, Kopecky KJ, Ruschulte J, Chen IM, Slovak ML, Karanes C, Godwin J, List A, Willman CL. Rimsza LM, et al. Among authors: karanes c. Leukemia. 2000 Jun;14(6):1044-51. doi: 10.1038/sj.leu.2401699. Leukemia. 2000. PMID: 10865971 Review.

2

A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.

Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, Vial RH, Lichtin A, Nand S, Samlowski WE, Appelbaum FR. Karanes C, et al. Leuk Res. 1999 Sep;23(9):787-94. doi: 10.1016/s0145-2126(99)00087-9. Leuk Res. 1999. PMID: 10475617 Clinical Trial.

3

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR. List AF, et al. Among authors: karanes c. Blood. 2001 Dec 1;98(12):3212-20. doi: 10.1182/blood.v98.12.3212. Blood. 2001. PMID: 11719356 Free article. Clinical Trial.

4

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

Dorr R, Karanes C, Spier C, Grogan T, Greer J, Moore J, Weinberger B, Schiller G, Pearce T, Litchman M, Dalton W, Roe D, List AF. Dorr R, et al. Among authors: karanes c. J Clin Oncol. 2001 Mar 15;19(6):1589-99. doi: 10.1200/JCO.2001.19.6.1589. J Clin Oncol. 2001. PMID: 11250987 Clinical Trial.

5

Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.

Ryan DH, Kopecky KJ, Head D, Gumbart CN, Grever MR, Karanes C, Weick JK, Coltman CA Jr. Ryan DH, et al. Among authors: karanes c. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):713-6. Cancer Treat Rep. 1987. PMID: 3475171

6

A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.

List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW. List AF, et al. Among authors: karanes c. Bone Marrow Transplant. 2000 Feb;25(3):283-91. doi: 10.1038/sj.bmt.1702114. Bone Marrow Transplant. 2000. PMID: 10673700 Clinical Trial.

7

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group. Larson RA, et al. Among authors: karanes c. Leukemia. 2002 Sep;16(9):1627-36. doi: 10.1038/sj.leu.2402677. Leukemia. 2002. PMID: 12200674 Clinical Trial.

8

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.

Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F. Viola D, et al. Among authors: karanes c. Leukemia. 2021 Jan;35(1):189-200. doi: 10.1038/s41375-020-0810-4. Epub 2020 Apr 16. Leukemia. 2021. PMID: 32296125 Free PMC article.

9

A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia.

Rosen PJ, Rankin C, Head DR, Boldt DH, Luthardt FW, Norwood T, Pugh RP, Karanes C, Appelbaum FR. Rosen PJ, et al. Among authors: karanes c. Leuk Res. 2000 Mar;24(3):183-7. doi: 10.1016/s0145-2126(99)00148-4. Leuk Res. 2000. PMID: 10738999 Clinical Trial.

10

A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia.

Kirschbaum MH, Synold T, Stein AS, Tuscano J, Zain JM, Popplewell L, Karanes C, O'Donnell MR, Pulone B, Rincon A, Wright J, Frankel P, Forman SJ, Newman EM. Kirschbaum MH, et al. Among authors: karanes c. Leukemia. 2011 Oct;25(10):1543-7. doi: 10.1038/leu.2011.124. Epub 2011 May 31. Leukemia. 2011. PMID: 21625235 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

114 results

Search Page

Filters